MorphoSys (MOR) will announce earnings on Thursday

MorphoSys (NASDAQ:MOR – Get Your Free Report ) is set to announce its earnings results after the market closes on Thursday, August 29th. Analysts expect the company to post earnings of ($0.50) per share for the quarter. Investors who are interested in registering for the company’s conference call can do so using this link.

MorphoSys price performance

NASDAQ MOR opened at $18.96 on Thursday. The company has a 50-day simple moving average of $18.55 and a 200-day simple moving average of $18.17. MorphoSys has a 52-week low of $4.18 and a 52-week high of $19.50. The company has a debt-to-equity ratio of 4.98, a quick ratio of 1.38, and a current ratio of 1.38. The stock has a market cap of $2.86 billion, a price-to-earnings ratio of -5.45 and a beta of 1.20.

About MorphoSys

(Get a free report)

MorphoSys AG, together with its subsidiaries, is engaged in the development and commercialization of medicines for patients suffering from various types of cancer in Europe, Asia and the United States. The company’s product line includes Pelabresib, which is in phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in phase 1/2 studies for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for autoimmune renal disease and relapsed/refractory multiple myeloma; Ianalumab, a candidate in phase 3 clinical trials for Sjögren’s disease, lupus nephritis and other autoimmune diseases; Abelacimab which is in phase 3 trials for the prevention of venous thromboembolism and cancer-related thrombosis; Setrusumab, which is in phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in phase 2b trials for adult obesity.

Read more

Get news and reviews for MorphoSys Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for MorphoSys and related companies with MarketBeat.com’s FREE daily email newsletter.